Shares of Amgen fell 2.55% to $241.43 at 16:41 EST on Friday, after two successive sessions in a row of losses. NASDAQ Composite is sliding 2% to $13,070.69, following last session’s upward trend, This seems, up until now, an all-around rough trend exchanging session today.

Amgen’s last close was $247.75, 14.60% below its 52-week high of $276.69.

Amgen’s Sales

Amgen’s sales growth is 6.3% for the ongoing quarter and 3.1% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 6.6% and a negative 1%, respectively.

Amgen’s Revenue

Year-on-year quarterly revenue growth grew by 12%, now sitting on 24.99B for the twelve trailing months.


Amgen’s last day, last week, and last month’s average volatility was a negative 1.34%, a negative 0.35%, and a positive 0.49%, respectively.

Amgen’s last day, last week, and last month’s high and low average amplitude percentage was 13.65%, 4.58%, and 2.70%, respectively.

Amgen’s Stock Yearly Top and Bottom Value

Amgen’s stock is valued at $241.43 at 16:41 EST, way below its 52-week high of $276.69 and way higher than its 52-week low of $177.05.

Amgen’s Moving Average

Amgen’s value is higher than its 50-day moving average of $235.92 and higher than its 200-day moving average of $238.96.

Previous days news about Amgen

Amgen drug shrunk 37% of lung cancer tumors in study. According to Bloomberg Quint on Thursday, 28 January, "An Amgen Inc. lung cancer drug shrunk tumors in 37% of patients for whom chemotherapy and other drugs hadn’t worked, and prevented malignancies from progressing for a median of 6.8 months, the company said on Thursday.", "That prompted Amgen to consider who are the best patients to treat and whether the drug works better on its own or in combination, Friberg said."


Please enter your comment!
Please enter your name here